Posts from September 2018.
After decades of advocates asking for cannabis to be removed as a Schedule I drug, on September 28, 2018, the DEA recognized that cannabis can have medicinal value and therefore the cannabis drug Epidiolex cannot be a Schedule I drug. Schedule I is reserved for drugs that have “no medicinal value” and have the potential to be highly addictive.
Specifically the DEA concluded that “Epidiolex no longer meets the criteria for placement in schedule I of the CSA.”
On June 25, 2018 the FDA had approved Epidiolex “for the treatment of seizures associated with two rare and severe forms ...
Stay Connected
Recent Posts
- Pashman Stein Walder Hayden P.C. Files Amicus Briefs Supporting ATACH and Seth Goldberg and Daniel E. Cohen Attend ATACH’s 2026 Lobby Days in Washington D.C.
- DOJ Reclassifies State-Licensed Medical Marijuana and Schedules Hearing for Full Reclassification
- The New Game-Day Drink: Hemp Beverages Enter Major Venues
